The Latest Breaking News from Johnson & Johnson (

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Johnson & Johnson is expected to release its fiscal third-quarter earnings next month, and analysts project a double-digit earnings rise.

More than 40 years after the unexpected deaths of seven people due to tainted medicine, Tylenol became the centre of attention again for a different reason.

Johnson Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

Johnson Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).